Whether sequences of genetic material can be patented has been a matter of heated debate for the past decade or more.
In many countries, patents have been granted for isolated gene sequences, methods of isolating sequences, methods of using sequences for diagnosing genetic diseases, and a whole range of other gene-related products and methods.
The US decision signalled the end of fears that patents could impede genetic research as well as the provision of diagnostic genetic tests. Or so many thought.
Share this article
But the patent landscape around genetic testing for the BRCA genes is, in fact, far more complex than this.
Read the full, original story here: For Myriad Genetics, the gene patent fight isn’t over yet
